Moreover, the coadministration of PD-L1 blockade with IDH1R132H inhibition and the standard of care (RT + TMZ) markedly enhanced the outcome of IDH1-mut glioma-bearing mice, counteracting T-cell exhaustion and eliciting an immunological memory with the generation of memory CD8+ T-cells [35]. Here, IDH1 is linked to central nervous system cancer.